BioNTech SE ADR [BNTX] stock is trading at $108.49, down -1.51%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BNTX shares have gain 13.23% over the last week, with a monthly amount glided 16.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioNTech SE ADR [NASDAQ: BNTX] stock has seen the most recent analyst activity on June 05, 2025, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $145 from $134. Previously, Goldman started tracking the stock with Neutral rating on May 29, 2025, and set its price target to $110. On March 13, 2025, Citigroup initiated with a Buy rating and assigned a price target of $145 on the stock. Truist started tracking the stock assigning a Buy rating and suggested a price target of $172 on January 10, 2025. Wells Fargo initiated its recommendation with a Overweight and recommended $170 as its price target on December 11, 2024. BMO Capital Markets reiterated a Outperform rating for this stock on December 02, 2024. In a note dated November 19, 2024, Evercore ISI upgraded an Outperform rating on this stock and boosted its target price from $110 to $125.
BioNTech SE ADR [BNTX] stock has fluctuated between $76.53 and $131.49 over the past year. Currently, Wall Street analysts expect the stock to reach $118.67 within the next 12 months. BioNTech SE ADR [NASDAQ: BNTX] shares were valued at $108.49 at the most recent close of the market. An investor can expect a potential return of 9.38% based on the average BNTX price forecast.
Analyzing the BNTX fundamentals
BioNTech SE ADR [NASDAQ:BNTX] reported sales of 2.97B for the trailing twelve months, which represents a drop of -5.51%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -0.39%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.04 and Total Capital is -0.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 107.69 points at the first support level, and at 106.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 110.00, and for the 2nd resistance point, it is at 111.51.
Ratios To Look Out For
For context, BioNTech SE ADR’s Current Ratio is 10.18. In addition, the Quick Ratio stands at 10.02 and the Cash Ratio stands at 6.64. Considering the valuation of this stock, the price to sales ratio is 8.79, the price to book ratio is 1.28.
Transactions by insiders
Recent insider trading involved Jeggle Helmut Wolfgang, Director, that happened on Jun 04 ’25 when 0.15 million shares were purchased. 10% Owner, ATHOS KG completed a deal on Jun 02 ’25 to buy 0.17 million shares. Meanwhile, 10% Owner ATHOS KG bought 0.5 million shares on May 28 ’25.
